Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Hoang
DB
David Hoang
Deutsche Bank
Wall Street Analyst
★★☆☆☆
#1878
on 13Foresight · ranked by our own returns
65%
Success Rate
-5.4%
Average Return
15 of 23 calls profitable · -26.3% vs benchmark
📈 Across the calls we could measure, roughly 65% of David Hoang's ratings turned a profit when each position was held for 2 year — averaging -5.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 4 Hold 4 Sell
David's Stock Coverage 22 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
PRAX
Praxis Precision Medicines
 Jun 02, 2026 BUY Strong Buy
+92.1% avg upside
24 analysts
$374.00
32.42% Upside
 +4.6%
DNLI
Denali Therapeutics
 May 22, 2026 BUY Strong Buy
+60.2% avg upside
24 analysts
$31.00
32.99% Upside
 +17.6%
SYRE
Spyre Therapeutics
 May 12, 2026 BUY Strong Buy
-15.4% avg upside
23 analysts
$102.00
15.53% Upside
 +11.4%
NBIX
Neurocrine
 May 07, 2026 HOLD Strong Buy
+7.8% avg upside
37 analysts
$155.00
2.05% Downside
 +6.8%
AXSM
Axsome Therapeutics
 May 05, 2026 BUY Strong Buy
-10.5% avg upside
28 analysts
$280.00
11.87% Upside
 +12.9%
APGE
Apogee Therapeutics
 Apr 02, 2026 BUY Strong Buy
+28.7% avg upside
19 analysts
$118.00
30.59% Upside
 +4.9%
ATAI
Atai Beckley N.V.
 Mar 26, 2026 BUY Strong Buy
+230.1% avg upside
16 analysts
$12.00
195.65% Upside
 +13.3%
SRPT
Sarepta Therapeutics
 Mar 26, 2026 SELL Buy
+246.5% avg upside
49 analysts
$14.00
20.24% Downside
 +27.4%
XENE
Xenon
 Mar 10, 2026 BUY Strong Buy
+19.0% avg upside
28 analysts
$90.00
70.02% Upside
 -13.6%
JAZZ
Jazz Pharmaceuticals
 Mar 05, 2026 BUY Strong Buy
-1.8% avg upside
35 analysts
$226.00
0.56% Upside
 +25.6%
HRMY
Harmony Biosciences Holdings
 Feb 25, 2026 HOLD Strong Buy
+39.5% avg upside
13 analysts
$30.00
9.91% Downside
 +6.7%
ALKS
Alkermes
 Nov 13, 2025 BUY Strong Buy
-17.5% avg upside
34 analysts
$45.00
0.07% Downside
 +46.2%
ACAD
ACADIA Pharmaceuticals
 Sep 25, 2025 BUY Strong Buy
+66.0% avg upside
42 analysts
$29.00
34.18% Upside
 +1.8%
BHVN
Biohaven Ltd.
 Feb 11, 2025 BUY Strong Buy
+87.5% avg upside
25 analysts
$65.00
378.99% Upside
 -68.1%
ABOS
Acumen Pharmaceuticals
 Jul 25, 2024 BUY Strong Buy
+258.9% avg upside
10 analysts
$7.00
209.72% Upside
 -31.1%
SLDB
Solid Biosciences
 Jul 17, 2024 BUY Strong Buy
+92.3% avg upside
23 analysts
$16.00
92.03% Upside
 -22.3%
VYGR
Voyager Therapeutics
 Mar 06, 2024 BUY Strong Buy
+284.7% avg upside
23 analysts
$16.00
330.06% Upside
 -57.8%
ALNY
Alnylam Pharma
 Apr 26, 2023 HOLD Strong Buy
+23.4% avg upside
51 analysts
$220.00
20.94% Downside
 +27.4%
ARWR
Arrowhead Pharmaceuticals
 Apr 26, 2023 BUY Strong Buy
-19.1% avg upside
26 analysts
$80.00
2.30% Downside
 -62.7%
GOSS
Gossamer Bio
 Dec 07, 2022 HOLD Buy
+4381.2% avg upside
17 analysts
$3.00
1685.77% Upside
 -65.3%
RDHL
RedHill Biopharma
 Sep 30, 2020 BUY Strong Buy
+2365.0% avg upside
7 analysts
$19.00
2234.68% Upside
 -95.1%
KRYS
Krystal Biotech
 Mar 12, 2020 BUY Strong Buy
-28.3% avg upside
19 analysts
$73.00
79.10% Downside
 +68.4%
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Hoang — Frequently Asked Questions
How accurate are David Hoang's stock ratings?
Based on the calls 13Foresight could measure, about 61% of David's ratings were profitable over a one-year hold, with an average return of -3.9% per rating, or -19.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Hoang is currently ranked #1878 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on PRAX, DNLI, SYRE, NBIX, AXSM, APGE, ATAI, SRPT, XENE, JAZZ, HRMY, ALKS and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.